Roivant Sciences Ltd. (NASDAQ: ROIV) reported Q2 EPS of ($0.48), $0.16 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $7.18 million.

For earnings history and earnings-related data on Roivant Sciences Ltd. (ROIV) click here.